A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...
After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...
Thermo Fisher plant in North Carolina flagged for contamination, air bubble issues in FDA inspection
Thermo Fisher Scientific is responsible for helping to produce some of the hottest drugs on the market, including Novo ...
Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...
Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...
Fast Company on MSN10d
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is overThe San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking ...
The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback